Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CT-P52 biosimilar vs Taltz in healthy subjects
NCT07200986Phase 1Active, not recruiting
- Sponsor
- Celltrion
- Start
- Sep 2025
- Primary completion
- Mar 2026
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of CT-P52 in psoriasis, psoriatic arthritis (PsA) and ankylosing spondylitis (AS) (2 arms), sponsored by Celltrion. Primary endpoints: Area Under the Concentration-Time Curve from Time Zero to Infinity at Day 85 and Maximum Plasma Concentration at Day 85. Started Sep 2025; status: active, not recruiting.
02
Drugs
CT-P52
03
Conditions
psoriasispsoriatic arthritis (PsA)ankylosing spondylitis (AS)
Beyond the preview
Go deeper on NCT07200986.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07200986.